Neuronetics Inc

Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.

Earnings data Q1 2023

Earnings data Q2 2023

Fintel reports that Cannell Capital has filed a 13D/A form with the SEC disclosing ownership of 3.13MM shares of Neuronetics Inc (STIM).

Cannell Capital Now Owns 11.03% of Neuronetics

Award recognizes NeuroStar for its significant contributions toward patient wellbeing Award recognizes NeuroStar for its significant contributions toward patient wellbeing

NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA

Neuronetics, Inc. (NASDAQ:STIM ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants Bill Plovanic - Canaccord Adam Maeder - Piper Sandler Margaret Kaczor - William Blair Daniel Stauder - JMP Securities Operator Good day and welcome to the Neuronetics Fourth Quarter and Full-Year 2022 Conference Call. At this time, all participants are in listen-only mode.

Neuronetics, Inc. (STIM) Q4 2022 Earnings Call Transcript

Neuronetics (STIM) delivered earnings and revenue surprises of 30.23% and 9.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

MALVERN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2022.

Neuronetics Reports Record Fourth Quarter and Record Full Year 2022 Financial and Operating Results

United HealthCare Optum Reduces Barriers to TMS Eligibility for Depression Patients United HealthCare Optum Reduces Barriers to TMS Eligibility for Depression Patients

Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives

MALVERN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to eight new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the award was approved by Neuronetics' Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Company Launches a New Educational Campaign For Providers Company Launches a New Educational Campaign For Providers

Neuronetics Expands NeuroStar® Advanced Therapy's Proprietary TrakStar® Platform

MALVERN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release fourth quarter 2022 financial and operating results prior to market open on Tuesday, March 7th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call

Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy

Neuronetics Sponsors the 5th International Brain Stimulation Conference

Brainsway

I am bullish on the niche industry that uses magnetic stimulation for brain therapies. BrainsWay and Neuronetics are US-listed stocks in this niche, however they are highly unprofitable with volatile sales growth.

Why I Am Passing On BrainsWay And Neuronetics

New Senior Leadership Role Will Streamline Alignment of All Company Revenue-Generating Functions New Senior Leadership Role Will Streamline Alignment of All Company Revenue-Generating Functions

Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer

Today, we revisit a small medical device company called Neuronetics for the first time since January 2021. The stock is up some 30% over that time as Neuronetics has seen some notable milestones and delivered consistent sales growth.

Neuronetics: An Overdue Checkup

NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS

Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners

MALVERN, Pa. and TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders (“Neuronetics”), and Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH), a leading provider of transcranial magnetic stimulation (“TMS”) therapy (“Greenbrook”), today announced an expanded commercial partnership through year end 2028.

Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership

Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety

Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health

MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it has settled the litigation filed in the District of Delaware against BrainsWay Ltd. and BrainsWay USA Inc. for unfair competition under the Lanham Act and state law.

Neuronetics Settles Litigation Against BrainsWay

MALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced certain preliminary unaudited fourth quarter and full year 2022 revenue results.

Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results

New Director Brings Extensive Experience to Poise the Company for Growth New Director Brings Extensive Experience to Poise the Company for Growth

Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors

Cardinal Health

Olink Holding AB

Silk Road Medical Inc

Transmedics Group Inc

Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.

5 Winning Medical Product Stocks That Still Have Room to Run

Here is how Neuronetics (STIM) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

Is Neuronetics (STIM) Stock Outpacing Its Medical Peers This Year?

Does Neuronetics (STIM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Neuronetics (STIM) Is Up 12.75% in One Week: What You Should Know

NeuroStar's technology once again recognized as an effective non-drug treatment for patients NeuroStar's technology once again recognized as an effective non-drug treatment for patients

Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category

The high prevalence of major depressive disorder creates the need for Neuronetics' NeuroStar Advanced Therapy System. Neuronetics is valued below its industry, leaving plenty of room to the upside for the stock.

Neuronetics: Numerous Expansion Opportunities Mean An Outperforming Stock

MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022. The Company is scheduled to present at the conference at 9:30 am Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at  ir.neuronetics.com . A replay of the webcast will be archived on the website for approximately 90 days. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn't helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 4.8 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world's largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com. Investor Contact: Mark KlausnerWestwicke Partners443-213-0501 ir@neuronetics.com Media Contact: EvolveMKD646.517.4220 NeuroStar@evolvemkd.com

News for Neuronetics Inc Stock (STIM)